Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lubiprostone.

Kate McKeage1, Greg L Plosker, M Asif A Siddiqui

  • 1Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz

Drugs
|May 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Risankizumab: First Global Approval.

Drugs·2019
Same author

Ravulizumab: First Global Approval.

Drugs·2019
Same author

<i>Ginkgo biloba</i> extract EGb 761<sup>®</sup> in the symptomatic treatment of mild-to-moderate dementia: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Lubiprostone significantly increased spontaneous bowel movements in patients with chronic idiopathic constipation. This medication was well-tolerated, with nausea as the most common side effect.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Chronic idiopathic constipation (CIC) affects a significant patient population.
  • Current treatments for CIC have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the efficacy and safety of lubiprostone in patients with CIC.
  • To assess the impact of lubiprostone on bowel movement frequency and stool characteristics.

Main Methods:

  • Two pivotal, randomized, double-blind, multicenter phase III studies were conducted.
  • Patients received either lubiprostone 24 mcg twice daily or placebo for 4 weeks.
  • Spontaneous bowel movements (SBMs), straining, stool consistency, and constipation severity were assessed.

Main Results:

Related Experiment Videos

  • Lubiprostone significantly increased the frequency of SBMs compared to placebo at all weekly timepoints (p < 0.05).
  • At week 1, lubiprostone increased mean SBMs from 1.3-1.5 to 5.9 per week, versus 4.0 for placebo (p < 0.0001).
  • Significant improvements in straining, stool consistency, and constipation severity were observed with lubiprostone (p < 0.05).

Conclusions:

  • Lubiprostone is an effective treatment for chronic idiopathic constipation.
  • The drug demonstrated a favorable safety profile, with nausea being the most common adverse event.